Loading…
Characteristics and outcomes of antiretroviral-treated HIV-HBV co-infected patients in Canada?
Hepatitis B (HBV) and Human Immunodeficiency Virus (HIV) share common risk factors for exposure. Co-infected patients have an increased liver-related mortality risk and may have accelerated HIV progression. The epidemiology and demographic characteristics of HIV-HBV co-infection in Canada remain poo...
Saved in:
| Published in: | BMC infectious diseases 2019-11, Vol.19 (1), p.982-982, Article 982 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c493t-552296c083d8b0a32ad45faedb77063b3abe21bfb03bbc871f8f67509cd880fc3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c493t-552296c083d8b0a32ad45faedb77063b3abe21bfb03bbc871f8f67509cd880fc3 |
| container_end_page | 982 |
| container_issue | 1 |
| container_start_page | 982 |
| container_title | BMC infectious diseases |
| container_volume | 19 |
| creator | Rana, Urvi Driedger, Matt Sereda, Paul Pan, Shenyi Ding, Erin Wong, Alex Walmsley, Sharon Klein, Marina Kelly, Deborah Loutfy, Mona Thomas, Rejean Sanche, Stephen Kroch, Abigail Machouf, Nima Roy-Gagnon, Marie-Helene Hogg, Robert Cooper, Curtis L |
| description | Hepatitis B (HBV) and Human Immunodeficiency Virus (HIV) share common risk factors for exposure. Co-infected patients have an increased liver-related mortality risk and may have accelerated HIV progression. The epidemiology and demographic characteristics of HIV-HBV co-infection in Canada remain poorly defined. We compared the demographic and clinical characteristics and factors associated with advanced hepatic fibrosis between HIV and HIV-HBV co-infected patients.
A retrospective cohort analysis was conducted using data from the Canadian Observational Cohort (CANOC) Collaboration, including eight sites from British Columbia, Quebec, and Ontario. Eligible participants were HIV-infected patients who initiated combination ARV between January 1, 2000 and December 14, 2014. Demographic and clinical characteristics were compared between HIV-HBV co-infected and HIV-infected groups using chi-square or Fisher exact tests for categorical variables, and Wilcoxon's Rank Sum test for continuous variables. Liver fibrosis was estimated by the AST to Platelet Ratio Index (APRI).
HBV status and APRI values were available for 2419 cohort participants. 199 (8%) were HBV co-infected. Compared to HIV-infected participants, HIV-HBV co-infected participants were more likely to use injection drugs (28% vs. 21%, p = 0.03) and be HCV-positive (31%, vs. 23%, p = 0.02). HIV-HBV co-infected participants had lower baseline CD4 T cell counts (188 cells/mm
, IQR: 120-360) compared to 235 cells/mm
in HIV-infected participants (IQR: 85-294) (p = 0.0002) and higher baseline median APRI scores (0.50 vs. 0.37, p |
| doi_str_mv | 10.1186/s12879-019-4617-8 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_816d216f5f324055af43f38d3fb908f4</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_816d216f5f324055af43f38d3fb908f4</doaj_id><sourcerecordid>2328376211</sourcerecordid><originalsourceid>FETCH-LOGICAL-c493t-552296c083d8b0a32ad45faedb77063b3abe21bfb03bbc871f8f67509cd880fc3</originalsourceid><addsrcrecordid>eNpdUstuFDEQtBCIhIUP4IJG4sLFxI-ZsecCghWwK0XiEnLEar8Sr2bHi-2JxN_jyYYoycn9qC51tQuht5R8pFT2Z5kyKQZM6IDbngosn6FT2gqKGeft8wfxCXqV844QKiQbXqITTkXHBBtO0e_1NSQwxaWQSzC5gck2cS4m7l1uoq95CcmVFG9CghGX5KA422y2l3jz9bIxEYfJO7PUDlCCm0puwtSsYQILn1-jFx7G7N7cvSv06_u3i_UGn__8sV1_OcemHXjBXcfY0BsiuZWaAGdg286Ds1oI0nPNQTtGtdeEa22koF76XnRkMFZK4g1foe2R10bYqUMKe0h_VYSgbgsxXSlIVd_olKS9ZbT3neesJV0HvuWeS8u9HoisyQp9OnIdZr131lRJVfkj0sedKVyrq3ijeil414pK8OGOIMU_s8tF7UM2bhxhcnHOii3nHwRtaYW-fwLdxTlN9VQVxSQXPaMLih5RJsWck_P3y1CiFieooxNUdYJanKBknXn3UMX9xP-v5_8ABzSvFA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2328376211</pqid></control><display><type>article</type><title>Characteristics and outcomes of antiretroviral-treated HIV-HBV co-infected patients in Canada?</title><source>Publicly Available Content Database</source><source>PubMed Central(OpenAccess)</source><creator>Rana, Urvi ; Driedger, Matt ; Sereda, Paul ; Pan, Shenyi ; Ding, Erin ; Wong, Alex ; Walmsley, Sharon ; Klein, Marina ; Kelly, Deborah ; Loutfy, Mona ; Thomas, Rejean ; Sanche, Stephen ; Kroch, Abigail ; Machouf, Nima ; Roy-Gagnon, Marie-Helene ; Hogg, Robert ; Cooper, Curtis L</creator><creatorcontrib>Rana, Urvi ; Driedger, Matt ; Sereda, Paul ; Pan, Shenyi ; Ding, Erin ; Wong, Alex ; Walmsley, Sharon ; Klein, Marina ; Kelly, Deborah ; Loutfy, Mona ; Thomas, Rejean ; Sanche, Stephen ; Kroch, Abigail ; Machouf, Nima ; Roy-Gagnon, Marie-Helene ; Hogg, Robert ; Cooper, Curtis L ; Canadian Observational Cohort (CANOC) Collaboration ; The Canadian Observational Cohort (CANOC) Collaboration</creatorcontrib><description>Hepatitis B (HBV) and Human Immunodeficiency Virus (HIV) share common risk factors for exposure. Co-infected patients have an increased liver-related mortality risk and may have accelerated HIV progression. The epidemiology and demographic characteristics of HIV-HBV co-infection in Canada remain poorly defined. We compared the demographic and clinical characteristics and factors associated with advanced hepatic fibrosis between HIV and HIV-HBV co-infected patients.
A retrospective cohort analysis was conducted using data from the Canadian Observational Cohort (CANOC) Collaboration, including eight sites from British Columbia, Quebec, and Ontario. Eligible participants were HIV-infected patients who initiated combination ARV between January 1, 2000 and December 14, 2014. Demographic and clinical characteristics were compared between HIV-HBV co-infected and HIV-infected groups using chi-square or Fisher exact tests for categorical variables, and Wilcoxon's Rank Sum test for continuous variables. Liver fibrosis was estimated by the AST to Platelet Ratio Index (APRI).
HBV status and APRI values were available for 2419 cohort participants. 199 (8%) were HBV co-infected. Compared to HIV-infected participants, HIV-HBV co-infected participants were more likely to use injection drugs (28% vs. 21%, p = 0.03) and be HCV-positive (31%, vs. 23%, p = 0.02). HIV-HBV co-infected participants had lower baseline CD4 T cell counts (188 cells/mm
, IQR: 120-360) compared to 235 cells/mm
in HIV-infected participants (IQR: 85-294) (p = 0.0002) and higher baseline median APRI scores (0.50 vs. 0.37, p < 0.0001). This difference in APRI was no longer clinically significant at follow-up (0.32 vs. 0.30, p = 0.03). HIV-HBV co-infected participants had a higher mortality rate compared to HIV-infected participants (11% vs. 7%, p = 0.02).
The prevalence, demographic and clinical characteristics of the HIV-HBV co-infected population in Canada is described. HIV-HBV co-infected patients have higher mortality, more advanced CD4 T cell depletion, and liver fibrosis that improves in conjunction with ARV therapy. The high prevalence of unknown HBV status demonstrates a need for increased screening among HIV-infected patients in Canada.</description><identifier>ISSN: 1471-2334</identifier><identifier>EISSN: 1471-2334</identifier><identifier>DOI: 10.1186/s12879-019-4617-8</identifier><identifier>PMID: 31752729</identifier><language>eng</language><publisher>England: BioMed Central</publisher><subject>Acquired immune deficiency syndrome ; Adult ; AIDS ; Anti-HIV Agents - administration & dosage ; Antiretroviral agents ; Antiretroviral drugs ; Antiviral Agents - administration & dosage ; British Columbia - epidemiology ; CD4 antigen ; Co-infection ; Coinfection - drug therapy ; Coinfection - epidemiology ; Coinfection - virology ; Continuity (mathematics) ; Demographics ; Depletion ; Epidemiology ; Female ; Fibrosis ; Health risks ; Hepatitis ; Hepatitis B ; Hepatitis B - drug therapy ; Hepatitis B - epidemiology ; Hepatitis B - virology ; Hepatitis B virus - drug effects ; Hepatitis B virus - genetics ; Hepatitis B virus - physiology ; Hepatocytes ; HIV ; HIV Infections - drug therapy ; HIV Infections - epidemiology ; HIV Infections - virology ; Human immunodeficiency virus ; Humans ; Infectious diseases ; Liver ; Lymphocytes ; Lymphocytes T ; Male ; Middle Aged ; Mortality ; Ontario - epidemiology ; Prevalence ; Quebec - epidemiology ; Retrospective Studies ; Risk analysis ; Risk Factors ; Viruses</subject><ispartof>BMC infectious diseases, 2019-11, Vol.19 (1), p.982-982, Article 982</ispartof><rights>2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s). 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c493t-552296c083d8b0a32ad45faedb77063b3abe21bfb03bbc871f8f67509cd880fc3</citedby><cites>FETCH-LOGICAL-c493t-552296c083d8b0a32ad45faedb77063b3abe21bfb03bbc871f8f67509cd880fc3</cites><orcidid>0000-0002-3368-3499</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6873547/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2328376211?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31752729$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rana, Urvi</creatorcontrib><creatorcontrib>Driedger, Matt</creatorcontrib><creatorcontrib>Sereda, Paul</creatorcontrib><creatorcontrib>Pan, Shenyi</creatorcontrib><creatorcontrib>Ding, Erin</creatorcontrib><creatorcontrib>Wong, Alex</creatorcontrib><creatorcontrib>Walmsley, Sharon</creatorcontrib><creatorcontrib>Klein, Marina</creatorcontrib><creatorcontrib>Kelly, Deborah</creatorcontrib><creatorcontrib>Loutfy, Mona</creatorcontrib><creatorcontrib>Thomas, Rejean</creatorcontrib><creatorcontrib>Sanche, Stephen</creatorcontrib><creatorcontrib>Kroch, Abigail</creatorcontrib><creatorcontrib>Machouf, Nima</creatorcontrib><creatorcontrib>Roy-Gagnon, Marie-Helene</creatorcontrib><creatorcontrib>Hogg, Robert</creatorcontrib><creatorcontrib>Cooper, Curtis L</creatorcontrib><creatorcontrib>Canadian Observational Cohort (CANOC) Collaboration</creatorcontrib><creatorcontrib>The Canadian Observational Cohort (CANOC) Collaboration</creatorcontrib><title>Characteristics and outcomes of antiretroviral-treated HIV-HBV co-infected patients in Canada?</title><title>BMC infectious diseases</title><addtitle>BMC Infect Dis</addtitle><description>Hepatitis B (HBV) and Human Immunodeficiency Virus (HIV) share common risk factors for exposure. Co-infected patients have an increased liver-related mortality risk and may have accelerated HIV progression. The epidemiology and demographic characteristics of HIV-HBV co-infection in Canada remain poorly defined. We compared the demographic and clinical characteristics and factors associated with advanced hepatic fibrosis between HIV and HIV-HBV co-infected patients.
A retrospective cohort analysis was conducted using data from the Canadian Observational Cohort (CANOC) Collaboration, including eight sites from British Columbia, Quebec, and Ontario. Eligible participants were HIV-infected patients who initiated combination ARV between January 1, 2000 and December 14, 2014. Demographic and clinical characteristics were compared between HIV-HBV co-infected and HIV-infected groups using chi-square or Fisher exact tests for categorical variables, and Wilcoxon's Rank Sum test for continuous variables. Liver fibrosis was estimated by the AST to Platelet Ratio Index (APRI).
HBV status and APRI values were available for 2419 cohort participants. 199 (8%) were HBV co-infected. Compared to HIV-infected participants, HIV-HBV co-infected participants were more likely to use injection drugs (28% vs. 21%, p = 0.03) and be HCV-positive (31%, vs. 23%, p = 0.02). HIV-HBV co-infected participants had lower baseline CD4 T cell counts (188 cells/mm
, IQR: 120-360) compared to 235 cells/mm
in HIV-infected participants (IQR: 85-294) (p = 0.0002) and higher baseline median APRI scores (0.50 vs. 0.37, p < 0.0001). This difference in APRI was no longer clinically significant at follow-up (0.32 vs. 0.30, p = 0.03). HIV-HBV co-infected participants had a higher mortality rate compared to HIV-infected participants (11% vs. 7%, p = 0.02).
The prevalence, demographic and clinical characteristics of the HIV-HBV co-infected population in Canada is described. HIV-HBV co-infected patients have higher mortality, more advanced CD4 T cell depletion, and liver fibrosis that improves in conjunction with ARV therapy. The high prevalence of unknown HBV status demonstrates a need for increased screening among HIV-infected patients in Canada.</description><subject>Acquired immune deficiency syndrome</subject><subject>Adult</subject><subject>AIDS</subject><subject>Anti-HIV Agents - administration & dosage</subject><subject>Antiretroviral agents</subject><subject>Antiretroviral drugs</subject><subject>Antiviral Agents - administration & dosage</subject><subject>British Columbia - epidemiology</subject><subject>CD4 antigen</subject><subject>Co-infection</subject><subject>Coinfection - drug therapy</subject><subject>Coinfection - epidemiology</subject><subject>Coinfection - virology</subject><subject>Continuity (mathematics)</subject><subject>Demographics</subject><subject>Depletion</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Fibrosis</subject><subject>Health risks</subject><subject>Hepatitis</subject><subject>Hepatitis B</subject><subject>Hepatitis B - drug therapy</subject><subject>Hepatitis B - epidemiology</subject><subject>Hepatitis B - virology</subject><subject>Hepatitis B virus - drug effects</subject><subject>Hepatitis B virus - genetics</subject><subject>Hepatitis B virus - physiology</subject><subject>Hepatocytes</subject><subject>HIV</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - epidemiology</subject><subject>HIV Infections - virology</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Liver</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Ontario - epidemiology</subject><subject>Prevalence</subject><subject>Quebec - epidemiology</subject><subject>Retrospective Studies</subject><subject>Risk analysis</subject><subject>Risk Factors</subject><subject>Viruses</subject><issn>1471-2334</issn><issn>1471-2334</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdUstuFDEQtBCIhIUP4IJG4sLFxI-ZsecCghWwK0XiEnLEar8Sr2bHi-2JxN_jyYYoycn9qC51tQuht5R8pFT2Z5kyKQZM6IDbngosn6FT2gqKGeft8wfxCXqV844QKiQbXqITTkXHBBtO0e_1NSQwxaWQSzC5gck2cS4m7l1uoq95CcmVFG9CghGX5KA422y2l3jz9bIxEYfJO7PUDlCCm0puwtSsYQILn1-jFx7G7N7cvSv06_u3i_UGn__8sV1_OcemHXjBXcfY0BsiuZWaAGdg286Ds1oI0nPNQTtGtdeEa22koF76XnRkMFZK4g1foe2R10bYqUMKe0h_VYSgbgsxXSlIVd_olKS9ZbT3neesJV0HvuWeS8u9HoisyQp9OnIdZr131lRJVfkj0sedKVyrq3ijeil414pK8OGOIMU_s8tF7UM2bhxhcnHOii3nHwRtaYW-fwLdxTlN9VQVxSQXPaMLih5RJsWck_P3y1CiFieooxNUdYJanKBknXn3UMX9xP-v5_8ABzSvFA</recordid><startdate>20191121</startdate><enddate>20191121</enddate><creator>Rana, Urvi</creator><creator>Driedger, Matt</creator><creator>Sereda, Paul</creator><creator>Pan, Shenyi</creator><creator>Ding, Erin</creator><creator>Wong, Alex</creator><creator>Walmsley, Sharon</creator><creator>Klein, Marina</creator><creator>Kelly, Deborah</creator><creator>Loutfy, Mona</creator><creator>Thomas, Rejean</creator><creator>Sanche, Stephen</creator><creator>Kroch, Abigail</creator><creator>Machouf, Nima</creator><creator>Roy-Gagnon, Marie-Helene</creator><creator>Hogg, Robert</creator><creator>Cooper, Curtis L</creator><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7T2</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-3368-3499</orcidid></search><sort><creationdate>20191121</creationdate><title>Characteristics and outcomes of antiretroviral-treated HIV-HBV co-infected patients in Canada?</title><author>Rana, Urvi ; Driedger, Matt ; Sereda, Paul ; Pan, Shenyi ; Ding, Erin ; Wong, Alex ; Walmsley, Sharon ; Klein, Marina ; Kelly, Deborah ; Loutfy, Mona ; Thomas, Rejean ; Sanche, Stephen ; Kroch, Abigail ; Machouf, Nima ; Roy-Gagnon, Marie-Helene ; Hogg, Robert ; Cooper, Curtis L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c493t-552296c083d8b0a32ad45faedb77063b3abe21bfb03bbc871f8f67509cd880fc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>Adult</topic><topic>AIDS</topic><topic>Anti-HIV Agents - administration & dosage</topic><topic>Antiretroviral agents</topic><topic>Antiretroviral drugs</topic><topic>Antiviral Agents - administration & dosage</topic><topic>British Columbia - epidemiology</topic><topic>CD4 antigen</topic><topic>Co-infection</topic><topic>Coinfection - drug therapy</topic><topic>Coinfection - epidemiology</topic><topic>Coinfection - virology</topic><topic>Continuity (mathematics)</topic><topic>Demographics</topic><topic>Depletion</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Fibrosis</topic><topic>Health risks</topic><topic>Hepatitis</topic><topic>Hepatitis B</topic><topic>Hepatitis B - drug therapy</topic><topic>Hepatitis B - epidemiology</topic><topic>Hepatitis B - virology</topic><topic>Hepatitis B virus - drug effects</topic><topic>Hepatitis B virus - genetics</topic><topic>Hepatitis B virus - physiology</topic><topic>Hepatocytes</topic><topic>HIV</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - epidemiology</topic><topic>HIV Infections - virology</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Liver</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Ontario - epidemiology</topic><topic>Prevalence</topic><topic>Quebec - epidemiology</topic><topic>Retrospective Studies</topic><topic>Risk analysis</topic><topic>Risk Factors</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rana, Urvi</creatorcontrib><creatorcontrib>Driedger, Matt</creatorcontrib><creatorcontrib>Sereda, Paul</creatorcontrib><creatorcontrib>Pan, Shenyi</creatorcontrib><creatorcontrib>Ding, Erin</creatorcontrib><creatorcontrib>Wong, Alex</creatorcontrib><creatorcontrib>Walmsley, Sharon</creatorcontrib><creatorcontrib>Klein, Marina</creatorcontrib><creatorcontrib>Kelly, Deborah</creatorcontrib><creatorcontrib>Loutfy, Mona</creatorcontrib><creatorcontrib>Thomas, Rejean</creatorcontrib><creatorcontrib>Sanche, Stephen</creatorcontrib><creatorcontrib>Kroch, Abigail</creatorcontrib><creatorcontrib>Machouf, Nima</creatorcontrib><creatorcontrib>Roy-Gagnon, Marie-Helene</creatorcontrib><creatorcontrib>Hogg, Robert</creatorcontrib><creatorcontrib>Cooper, Curtis L</creatorcontrib><creatorcontrib>Canadian Observational Cohort (CANOC) Collaboration</creatorcontrib><creatorcontrib>The Canadian Observational Cohort (CANOC) Collaboration</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals(OpenAccess)</collection><jtitle>BMC infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rana, Urvi</au><au>Driedger, Matt</au><au>Sereda, Paul</au><au>Pan, Shenyi</au><au>Ding, Erin</au><au>Wong, Alex</au><au>Walmsley, Sharon</au><au>Klein, Marina</au><au>Kelly, Deborah</au><au>Loutfy, Mona</au><au>Thomas, Rejean</au><au>Sanche, Stephen</au><au>Kroch, Abigail</au><au>Machouf, Nima</au><au>Roy-Gagnon, Marie-Helene</au><au>Hogg, Robert</au><au>Cooper, Curtis L</au><aucorp>Canadian Observational Cohort (CANOC) Collaboration</aucorp><aucorp>The Canadian Observational Cohort (CANOC) Collaboration</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Characteristics and outcomes of antiretroviral-treated HIV-HBV co-infected patients in Canada?</atitle><jtitle>BMC infectious diseases</jtitle><addtitle>BMC Infect Dis</addtitle><date>2019-11-21</date><risdate>2019</risdate><volume>19</volume><issue>1</issue><spage>982</spage><epage>982</epage><pages>982-982</pages><artnum>982</artnum><issn>1471-2334</issn><eissn>1471-2334</eissn><abstract>Hepatitis B (HBV) and Human Immunodeficiency Virus (HIV) share common risk factors for exposure. Co-infected patients have an increased liver-related mortality risk and may have accelerated HIV progression. The epidemiology and demographic characteristics of HIV-HBV co-infection in Canada remain poorly defined. We compared the demographic and clinical characteristics and factors associated with advanced hepatic fibrosis between HIV and HIV-HBV co-infected patients.
A retrospective cohort analysis was conducted using data from the Canadian Observational Cohort (CANOC) Collaboration, including eight sites from British Columbia, Quebec, and Ontario. Eligible participants were HIV-infected patients who initiated combination ARV between January 1, 2000 and December 14, 2014. Demographic and clinical characteristics were compared between HIV-HBV co-infected and HIV-infected groups using chi-square or Fisher exact tests for categorical variables, and Wilcoxon's Rank Sum test for continuous variables. Liver fibrosis was estimated by the AST to Platelet Ratio Index (APRI).
HBV status and APRI values were available for 2419 cohort participants. 199 (8%) were HBV co-infected. Compared to HIV-infected participants, HIV-HBV co-infected participants were more likely to use injection drugs (28% vs. 21%, p = 0.03) and be HCV-positive (31%, vs. 23%, p = 0.02). HIV-HBV co-infected participants had lower baseline CD4 T cell counts (188 cells/mm
, IQR: 120-360) compared to 235 cells/mm
in HIV-infected participants (IQR: 85-294) (p = 0.0002) and higher baseline median APRI scores (0.50 vs. 0.37, p < 0.0001). This difference in APRI was no longer clinically significant at follow-up (0.32 vs. 0.30, p = 0.03). HIV-HBV co-infected participants had a higher mortality rate compared to HIV-infected participants (11% vs. 7%, p = 0.02).
The prevalence, demographic and clinical characteristics of the HIV-HBV co-infected population in Canada is described. HIV-HBV co-infected patients have higher mortality, more advanced CD4 T cell depletion, and liver fibrosis that improves in conjunction with ARV therapy. The high prevalence of unknown HBV status demonstrates a need for increased screening among HIV-infected patients in Canada.</abstract><cop>England</cop><pub>BioMed Central</pub><pmid>31752729</pmid><doi>10.1186/s12879-019-4617-8</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-3368-3499</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1471-2334 |
| ispartof | BMC infectious diseases, 2019-11, Vol.19 (1), p.982-982, Article 982 |
| issn | 1471-2334 1471-2334 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_816d216f5f324055af43f38d3fb908f4 |
| source | Publicly Available Content Database; PubMed Central(OpenAccess) |
| subjects | Acquired immune deficiency syndrome Adult AIDS Anti-HIV Agents - administration & dosage Antiretroviral agents Antiretroviral drugs Antiviral Agents - administration & dosage British Columbia - epidemiology CD4 antigen Co-infection Coinfection - drug therapy Coinfection - epidemiology Coinfection - virology Continuity (mathematics) Demographics Depletion Epidemiology Female Fibrosis Health risks Hepatitis Hepatitis B Hepatitis B - drug therapy Hepatitis B - epidemiology Hepatitis B - virology Hepatitis B virus - drug effects Hepatitis B virus - genetics Hepatitis B virus - physiology Hepatocytes HIV HIV Infections - drug therapy HIV Infections - epidemiology HIV Infections - virology Human immunodeficiency virus Humans Infectious diseases Liver Lymphocytes Lymphocytes T Male Middle Aged Mortality Ontario - epidemiology Prevalence Quebec - epidemiology Retrospective Studies Risk analysis Risk Factors Viruses |
| title | Characteristics and outcomes of antiretroviral-treated HIV-HBV co-infected patients in Canada? |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T20%3A12%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Characteristics%20and%20outcomes%20of%20antiretroviral-treated%20HIV-HBV%20co-infected%20patients%20in%20Canada?&rft.jtitle=BMC%20infectious%20diseases&rft.au=Rana,%20Urvi&rft.aucorp=Canadian%20Observational%20Cohort%20(CANOC)%20Collaboration&rft.date=2019-11-21&rft.volume=19&rft.issue=1&rft.spage=982&rft.epage=982&rft.pages=982-982&rft.artnum=982&rft.issn=1471-2334&rft.eissn=1471-2334&rft_id=info:doi/10.1186/s12879-019-4617-8&rft_dat=%3Cproquest_doaj_%3E2328376211%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c493t-552296c083d8b0a32ad45faedb77063b3abe21bfb03bbc871f8f67509cd880fc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2328376211&rft_id=info:pmid/31752729&rfr_iscdi=true |